早期活动与重症患者深静脉血栓发生率及死亡率的相关性:PREVENT试验的事后分析
本研究为多中心PREVENT试验的事后分析,纳入预期ICU停留≥72小时、接受药物血栓预防的重症患者1708例,用8分序数量表记录前3个ICU日的活动水平并分为4-7级、1-3级和0级三组。结果仅85例(5.0%)达到早期活动4-7级,356例(20.8%)为1-3级,1267例(74.2%)为0级。校正随机分组等协变量后,早期活动4-7级和1-3级与近端下肢深静脉血栓发生率无显著差异,但与90天死亡率降低相关(aHR 0.47,95%CI 0.22-1.01,p=0.052;aHR 0.43,95%CI 0.30-0.62,p<0.0001)。作者认为该关联不能确立因果关系,需随机对照试验评估其可改变程度。
要点
- 1708例预期ICU停留≥72小时的重症患者中,仅85例(5.0%)在前3个ICU日达到早期活动4-7级(至少主动站立),1267例(74.2%)为0级(被动关节活动)。
- 早期活动4-7级组近端下肢深静脉血栓1/85(1.3%)、1-3级组7/348(2.0%)、0级组50/1230(4.1%),校正后与0级组相比均无显著差异(aHR 1.19,95%CI 0.16-8.90,p=0.87;aHR 0.91,95%CI 0.39-2.12,p=0.83)。
- 早期活动4-7级组90天死亡率aHR 0.47(95%CI 0.22-1.01,p=0.052),1-3级组aHR 0.43(95%CI 0.30-0.62,p<0.0001),均低于0级组。
- 早期活动4-7级和1-3级患者病情严重程度、股静脉中心静脉导管和器官支持均少于0级患者。
- 作者认为早期活动与死亡率降低的关联不能确立因果关系,需随机对照试验评估该关联是否及在多大程度上可改变。
适用人群与场景
- 多中心PREVENT试验纳入的接受药物血栓预防、预期ICU停留≥72小时的重症患者,本分析共1708例。
诊断标准与关键阈值
- 活动水平用8分序数量表每日记录至ICU第28天;按前3个ICU日活动水平分为4-7级(至少主动站立)、1-3级(床椅被动转移或主动坐起)、0级(被动关节活动)。
研究设计与关键结果
- 研究类型:多中心PREVENT试验的事后分析;人群:接受药物血栓预防、预期ICU停留≥72小时的重症患者1708例;暴露:前3个ICU日早期活动水平分组(4-7级、1-3级、0级)。
- 活动水平分布:4-7级85例(5.0%),1-3级356例(20.8%),0级1267例(74.2%)。
- 近端下肢深静脉血栓:4-7级组1/85(1.3%),1-3级组7/348(2.0%),0级组50/1230(4.1%);与0级组相比,4-7级组aHR 1.19(95%CI 0.16-8.90,p=0.87),1-3级组aHR 0.91(95%CI 0.39-2.12,p=0.83),均无显著差异。
- 90天死亡率:与0级组相比,4-7级组aHR 0.47(95%CI 0.22-1.01,p=0.052),1-3级组aHR 0.43(95%CI 0.30-0.62,p<0.0001)。
- 基线特征:早期活动4-7级和1-3级患者病情严重程度、股静脉中心静脉导管和器官支持均少于0级患者。
证据类型、等级与局限
- 证据类型:多中心随机对照试验PREVENT的事后分析。
- 局限:作者指出该关联不能确立因果关系,需随机对照试验评估该关联是否及在多大程度上可改变。
对床旁实践的改变
- 作者认为早期活动与90天死亡率降低相关,但与近端下肢深静脉血栓发生率无显著差异。
- 作者认为该关联不能确立因果关系,需随机对照试验评估早期活动与死亡率关联是否及在多大程度上可改变。
指南或共识出处
- PREVENT试验(ClinicalTrials.gov ID:NCT02040103,2013年11月3日注册;Current controlled trials ID:ISRCTN44653506,2013年10月30日注册)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: This study assessed the mobility levels among critically ill patients and the association of early mobility with incident proximal lower-limb deep-vein thrombosis and 90-day mortality.
METHODS: This was a post hoc analysis of the multicenter PREVENT trial, which evaluated adjunctive intermittent pneumatic compression in critically ill patients receiving pharmacologic thromboprophylaxis with an expected ICU stay ≥ 72 h and found no effect on the primary outcome of incident proximal lower-limb deep-vein thrombosis. Mobility levels were documented daily up to day 28 in the ICU using a tool with an 8-point ordinal scale. We categorized patients according to mobility levels within the first 3 ICU days into three groups: early mobility level 4-7 (at least active standing), 1-3 (passive transfer from bed to chair or active sitting), and 0 (passive range of motion). We evaluated the association of early mobility and incident lower-limb deep-vein thrombosis and 90-day mortality by Cox proportional models adjusting for randomization and other co-variables.
RESULTS: Of 1708 patients, only 85 (5.0%) had early mobility level 4-7 and 356 (20.8%) level 1-3, while 1267 (74.2%) had early mobility level 0. Patients with early mobility levels 4-7 and 1-3 had less illness severity, femoral central venous catheters, and organ support compared to patients with mobility level 0. Incident proximal lower-limb deep-vein thrombosis occurred in 1/85 (1.3%) patients in the early mobility 4-7 group, 7/348 (2.0%) patients in mobility 1-3 group, and 50/1230 (4.1%) patients in mobility 0 group. Compared with early mobility group 0, mobility groups 4-7 and 1-3 were not associated with differences in incident proximal lower-limb deep-vein thrombosis (adjusted hazard ratio [aHR] 1.19, 95% confidence interval [CI] 0.16, 8.90; p = 0.87 and 0.91, 95% CI 0.39, 2.12; p = 0.83, respectively). However, early mobility groups 4-7 and 1-3 had lower 90-day mortality (aHR 0.47, 95% CI 0.22, 1.01; p = 0.052, and 0.43, 95% CI 0.30, 0.62; p < 0.0001, respectively).
CONCLUSIONS: Only a small proportion of critically ill patients with an expected ICU stay ≥ 72 h were mobilized early. Early mobility was associated with reduced mortality, but not with different incidence of deep-vein thrombosis. This association does not establish causality, and randomized controlled trials are required to assess whether and to what extent this association is modifiable.
TRIAL REGISTRATION: The PREVENT trial is registered at ClinicalTrials.gov, ID: NCT02040103 (registered on 3 November 2013) and Current controlled trials, ID: ISRCTN44653506 (registered on 30 October 2013).
参考来源
- Al-Dorzi HM, AlQahtani S, Al-Dawood A, et al. Association of early mobility with the incidence of deep-vein thrombosis and mortality among critically ill patients: a post hoc analysis of PREVENT trial. Crit Care. 2023. PMID: 36869382. doi:10.1186/s13054-023-04333-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。